Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Galectin

Galectins are a class of proteins that bind specifically to β-galactoside sugars, such as N-acetyllactosamine (Galβ1-3GlcNAc or Galβ1-4GlcNAc), which can be bound to proteins by either N-linked or O-linked glycosylation. They are also termed S-type lectins due to their dependency on disulphide bonds for stability and carbohydrate binding. There have been about 15 galectins discovered in mammals, encoded by the LGALS genes, which are numbered in a consecutive manner. Only galectin-1, -2, -3, -4, -7, -7B, -8, -9, -9B, 9C, -10, -12, -13, -14, and -16 have been identified in humans. Galectin-5 and -6 are found in rodents, whereas galectin-11 and -15 are uniquely found in sheep and goats. Members of the galectin family have also been discovered in other mammals, birds, amphibians, fish, nematodes, sponges, and some fungi. Unlike the majority of lectins they are not membrane bound, but soluble proteins with both intra- and extracellular functions. They have distinct but overlapping distributions[2] but found primarily in the cytosol, nucleus, extracellular matrix or in circulation. Although many galectins must be secreted, they do not have a typical signal peptide required for classical secretion. The mechanism and reason for this non-classical secretion pathway is unknown.

TD139
T51211450824-22-2In house
TD139 is a small molecule inhibitor of inhaled galectin-3 (Gal-3) with potential anti-fibrotic activity, commonly used in the study of idiopathic pulmonary fibrosis.
  • $64
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
GB1107
T153721978336-61-6
GB1107 is an effective and selective Galectin-3 inhibitor with a Kd of 37 nM.
  • $53
In Stock
Size
QTY
OTX008
T16413286936-40-1
OTX008 (PTX008) is a selective galectin-1 inhibitor.
  • $64
In Stock
Size
QTY
Thiodigalactoside
T3807451555-87-4
Thiodigalactoside (TDG), a non-metabolizable disaccharide, serves as an orally active, potent galectin (GAL) inhibitor, exhibiting Kd values of 24 μM and 49 μM for GAL1 and GAL3, respectively. Demonstrating anti-inflammatory and anti-cancer properties, it significantly diminishes body weight gain in diet-induced obese rats.
  • $34
In Stock
Size
QTY
TargetMol | Inhibitor Sale
G3-C12 acetate(848301-94-0 free base)
T11346L
G3-C12 acetate shows anticancer activity. is a galectin-3 binding peptide, with Kd of 88 nM.
  • $48
In Stock
Size
QTY
TargetMol | Inhibitor Sale
SNAP 398299
T28822903878-06-8In house
SNAP 398299 is a Glycopeptide Receptor Type 3 (Gal3) antagonist with anxiolytic and antidepressant-like effects and is used in the study of mood disorders.
  • $1,520
1-2 weeks
Size
QTY
DB21, Galectin-1 Antagonist
T826051623027-80-4
DB21, Galectin-1 Antagonist, is a peptidomimetic conjugated with dibenzofuran, serving as an allosteric inhibitor of galectin-1 (GAL1) interactions with glycans on cell surfaces. This compound enhances the inhibition of angiogenesis and tumor growth in melanoma, lung adenocarcinoma, and ovarian cancer models [1].
  • Inquiry Price
Size
QTY
Galectin-3/galectin-8-IN-1
T79380
Galectin-3 galectin-8-IN-1 (Compound 53) serves as a dual inhibitor of the Galectin-3 and galectin-8 C-terminal domains, exhibiting dissociation constants (Kd) of 4.12 μM for Galectin-3 and 6.04 μM for galectin-8. It effectively impedes the migration of MRC-5 lung fibroblast cells and is utilized in cancer and tissue fibrosis research [1].
  • Inquiry Price
Size
QTY
Galectin-3/galectin-8-IN-2
T79381
Galectin-3 galectin-8-IN-2 (Compound 57) is a dual inhibitor targeting the C-terminal domains of Galectin-3 and galectin-8, with dissociation constants (Kd) of 12.8 μM and 2.06 μM, respectively. It effectively inhibits MRC-5 lung fibroblast cell migration and serves as a potential research tool for studying cancer and tissue fibrosis [1].
  • Inquiry Price
Size
QTY
Galectin-3 antagonist 2
T745382921603-02-1
Galectin-3, a β-galactoside-specific carbohydrate recognition protein (lectin), facilitates the migration of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells and demonstrates resistance to pharmaceutical interventions.
  • $1,520
8-10 weeks
Size
QTY